RxDoctor Payments Data

Nina Nation, PA

Physician Assistant · Las Vegas, NVNPI 1255321774

Payments from drug & device makers

$2,105in general payments, 2019–2025

Across 97 payments — averaging $21.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$484
  • Novo Nordisk$343
  • AbbVie$259
  • Amgen$203
  • Intuitive Surgical$140
  • Astellas Pharma US Inc$93
  • plus $582 from 17 others

What the payments were for

  • Food & beverage$2,105100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,105 in reported general payments places this provider in the 75th percentile of 881 physician assistant providers in Nevada.

See all physician assistant providers in Nevada

Medicare billing

Part B allowed, 2024
$82,383
Medicare patients
286
Services billed
1,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$36,606
TrulicityDulaglutide16$26,572
FarxigaDapagliflozin Propanediol16$24,397
MounjaroTirzepatide19$20,810
EliquisApixaban13$11,626
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$11,327
Levothyroxine Sodium188$1,863
SynthroidLevothyroxine Sodium23$1,751
Atorvastatin Calcium198$1,642
Amlodipine Besylate181$1,609
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,603
Albuterol Sulfate HfaAlbuterol Sulfate62$1,469
Glipizide23$1,318
Losartan Potassium132$1,192
Wixela InhubFluticasone Propion/Salmeterol14$1,164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$86$47,38235 claims
Novo NordiskOzempic$343$36,60635 claims
AstraZenecaFarxiga, Breztri Aerosphere$43$35,72427 claims
PfizerEliquis$484$11,62613 claims
AbbVieSynthroid$259$1,75123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 881 physician assistant providers in Nevada.

Other physician assistant in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →